{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"DSMM XVII","nct_id":"NCT03948035","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dsmm-xvii-nct03948035. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide","label":"E-KRd/ Arm A","type":"EXPERIMENTAL"},{"description":"Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide","label":"KRd/ Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":["ClinAssess GmbH","Arbeitsgemeinschaft medikamentoese Tumortherapie"],"completion_date":{"date":"2029-08","type":"ESTIMATED"},"conditions":["Newly Diagnosed Multiple Myeloma"],"enrollment":{"count":576,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elotuzumab","otherNames":["Empliciti®"],"type":"DRUG"},{"name":"Carfilzomib","otherNames":["Kyprolis®"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":["Revlimid®"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Fortecortin®"],"type":"DRUG"},{"name":"autologous stem cell transplant","otherNames":[],"type":"OTHER"}],"last_update":"2023-05-06","lead_sponsor":"Wuerzburg University Hospital","official_title":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Induction phase","timeFrame":"At the end of Cycle 6 (168 days for all cycles plus up to 36 days)"},{"measure":"Maintenance phase","timeFrame":"3 years from randomisation"}],"references":[{"citation":"Rassner M, Baur R, Wasch R, Schiffer M, Schneider J, Mackensen A, Engelhardt M. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol. 2021 Jan 18;22(1):32. doi: 10.1186/s12882-020-02226-5.","pmid":"33461512","type":"DERIVED"}],"start_date":{"date":"2018-08-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","url":"https://clinicaltrials.gov/study/NCT03948035"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dsmm-xvii-nct03948035"}